MX2014010987A - Tratamiento de esclerosis multiple con anticuerpo anti-cd19. - Google Patents

Tratamiento de esclerosis multiple con anticuerpo anti-cd19.

Info

Publication number
MX2014010987A
MX2014010987A MX2014010987A MX2014010987A MX2014010987A MX 2014010987 A MX2014010987 A MX 2014010987A MX 2014010987 A MX2014010987 A MX 2014010987A MX 2014010987 A MX2014010987 A MX 2014010987A MX 2014010987 A MX2014010987 A MX 2014010987A
Authority
MX
Mexico
Prior art keywords
treatment
multiple sclerosis
antibody
cdc
apoptosis
Prior art date
Application number
MX2014010987A
Other languages
English (en)
Inventor
Ronald Herbst
Laura Lee Carter
Yue Wang
Volker Armin Knappertz
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2014010987A publication Critical patent/MX2014010987A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

La presente invención proporciona el tratamiento de la esclerosis múltiple mediante el uso de versiones quiméricas y humanizadas de anticuerpos anti-CD19 que pueden mediar la ADCC, CDC y/o apoptosis.
MX2014010987A 2012-03-12 2013-03-11 Tratamiento de esclerosis multiple con anticuerpo anti-cd19. MX2014010987A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261609704P 2012-03-12 2012-03-12
PCT/US2013/030247 WO2013138244A2 (en) 2012-03-12 2013-03-11 Treatment of multiple sclerosis with anti-cd19 antibody

Publications (1)

Publication Number Publication Date
MX2014010987A true MX2014010987A (es) 2015-03-03

Family

ID=49161934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010987A MX2014010987A (es) 2012-03-12 2013-03-11 Tratamiento de esclerosis multiple con anticuerpo anti-cd19.

Country Status (11)

Country Link
US (1) US20150044168A1 (es)
EP (1) EP2827902A4 (es)
JP (1) JP2015515456A (es)
KR (1) KR20140148411A (es)
CN (1) CN104640560A (es)
AU (1) AU2013232386A1 (es)
CA (1) CA2866943A1 (es)
HK (1) HK1206283A1 (es)
MX (1) MX2014010987A (es)
RU (1) RU2014141056A (es)
WO (1) WO2013138244A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
EP3149046B1 (en) * 2015-07-24 2020-02-26 Innovative Cellular Therapeutics Co., Ltd. Humanized anti-cd19 antibody and use thereof
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CN102512675A (zh) * 2004-06-04 2012-06-27 健泰科生物技术公司 用于治疗多发性硬化的方法
JP5825756B2 (ja) * 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１９を標的とする最適化抗体
PL2066349T3 (pl) * 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
AU2010221099A1 (en) * 2009-03-06 2011-09-22 Medimmune, Llc Humanized anti-CD19 antibody formulations

Also Published As

Publication number Publication date
AU2013232386A1 (en) 2014-10-16
CA2866943A1 (en) 2013-09-19
KR20140148411A (ko) 2014-12-31
WO2013138244A3 (en) 2014-12-24
AU2013232386A8 (en) 2014-10-23
EP2827902A2 (en) 2015-01-28
EP2827902A4 (en) 2016-01-20
CN104640560A (zh) 2015-05-20
RU2014141056A (ru) 2016-05-10
JP2015515456A (ja) 2015-05-28
WO2013138244A2 (en) 2013-09-19
WO2013138244A8 (en) 2014-09-18
US20150044168A1 (en) 2015-02-12
HK1206283A1 (en) 2016-01-08

Similar Documents

Publication Publication Date Title
IL290425A (en) Humanized, murine or chimeric anti-cd47 monoclonal antibodies
NZ736728A (en) Cd123 antibodies and conjugates thereof
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
ZA201804077B (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
IL256562A (en) Human cd3 antibodies or chimeras
HK1231369A1 (zh) 人源化或嵌合 抗體
GEP20227438B (en) Pd-1-binding molecules and methods of use thereof
NZ766356A (en) Anti-pd-1 antibodies
EP3702372A3 (en) Anti-cd40 human antibodies
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
MX2017011432A (es) Anticuerpos contra cumulo de diferenciacion 48 (cd48) y sus conjugados.
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
EP3294766C0 (en) HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3
TN2014000107A1 (en) Anti-aplhabetatcr antibody
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
WO2015009740A3 (en) Anti-mucin 1 binding agents and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2014010987A (es) Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
HK1255635A1 (zh) 人源化或嵌合的cd3抗體